CN114938634A - 用于胃驻留系统的释放速率调节膜的配方 - Google Patents

用于胃驻留系统的释放速率调节膜的配方 Download PDF

Info

Publication number
CN114938634A
CN114938634A CN202080091842.6A CN202080091842A CN114938634A CN 114938634 A CN114938634 A CN 114938634A CN 202080091842 A CN202080091842 A CN 202080091842A CN 114938634 A CN114938634 A CN 114938634A
Authority
CN
China
Prior art keywords
arm
pdl
pcl
peg
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091842.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·阿尔特雷特尔
A·韦特
S·穆尔蒂
T·塔伊
E·贝金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lindera Treatment Co
Original Assignee
Lindera Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindera Treatment Co filed Critical Lindera Treatment Co
Publication of CN114938634A publication Critical patent/CN114938634A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080091842.6A 2019-11-08 2020-11-06 用于胃驻留系统的释放速率调节膜的配方 Pending CN114938634A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933313P 2019-11-08 2019-11-08
US62/933,313 2019-11-08
PCT/US2020/059536 WO2021092486A1 (en) 2019-11-08 2020-11-06 Formulations for release-rate modulating films for gastric residence systems

Publications (1)

Publication Number Publication Date
CN114938634A true CN114938634A (zh) 2022-08-23

Family

ID=75849585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091842.6A Pending CN114938634A (zh) 2019-11-08 2020-11-06 用于胃驻留系统的释放速率调节膜的配方

Country Status (7)

Country Link
US (1) US20220387310A1 (https=)
EP (1) EP4054642A4 (https=)
JP (1) JP2022554383A (https=)
CN (1) CN114938634A (https=)
AU (1) AU2020378437A1 (https=)
CA (1) CA3160660A1 (https=)
WO (1) WO2021092486A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121360261A (zh) * 2025-12-23 2026-01-20 天津和治友德制药有限公司 一种生物膜基材、制备方法及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060631A (ko) * 2018-10-16 2021-05-26 리써치 트라이앵글 인스티튜트 피하 생분해성 저장소 디바이스
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
MX2021011314A (es) 2019-03-20 2021-12-10 Lyndra Therapeutics Inc Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
JP2022525482A (ja) 2019-03-20 2022-05-16 リンドラ セラピューティクス， インコーポレイティド 胃内滞留剤形用のコーティング
CN116234540A (zh) 2020-07-29 2023-06-06 赛康特集团有限责任公司 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017264A1 (en) * 2011-07-15 2013-01-17 Piramal Life Sciences Limited Alginate tube drug delivery system and method therefor
US20130273135A1 (en) * 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
WO2019060458A1 (en) * 2017-09-20 2019-03-28 Lyndra, Inc. ENCAPSULATION OF GASTRIC SYSTEMS
US20190133936A1 (en) * 2014-06-11 2019-05-09 Massachusetts Institute Of Technology Residence structures and related methods
US20190209090A1 (en) * 2017-11-28 2019-07-11 Massachusetts Institute Of Technology Gastric resident electronics
US20190231697A1 (en) * 2016-09-30 2019-08-01 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2015119653A1 (en) * 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US20170266112A1 (en) * 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
HK1258050A1 (zh) * 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
EP3547974B1 (en) * 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273135A1 (en) * 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
US20130017264A1 (en) * 2011-07-15 2013-01-17 Piramal Life Sciences Limited Alginate tube drug delivery system and method therefor
US20190133936A1 (en) * 2014-06-11 2019-05-09 Massachusetts Institute Of Technology Residence structures and related methods
US20190231697A1 (en) * 2016-09-30 2019-08-01 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
TW201902459A (zh) * 2017-06-09 2019-01-16 美商萊恩卓公司 具有釋放速率調節膜之胃的滯留系統
WO2019060458A1 (en) * 2017-09-20 2019-03-28 Lyndra, Inc. ENCAPSULATION OF GASTRIC SYSTEMS
US20190209090A1 (en) * 2017-11-28 2019-07-11 Massachusetts Institute Of Technology Gastric resident electronics

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121360261A (zh) * 2025-12-23 2026-01-20 天津和治友德制药有限公司 一种生物膜基材、制备方法及应用

Also Published As

Publication number Publication date
JP2022554383A (ja) 2022-12-28
AU2020378437A1 (en) 2022-06-02
CA3160660A1 (en) 2021-05-14
EP4054642A4 (en) 2024-02-28
EP4054642A1 (en) 2022-09-14
US20220387310A1 (en) 2022-12-08
WO2021092486A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
CN114938634A (zh) 用于胃驻留系统的释放速率调节膜的配方
JP7588177B2 (ja) 放出速度調節フィルムを有する胃内滞留システム
US20220387311A1 (en) Gastric residence systems for administration of active agents
JP7433351B2 (ja) ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
JP2015528450A (ja) エタノールの影響に対して耐性を有する胃液抵抗性の医薬組成物又は栄養補助組成物
US20090017110A1 (en) Modified release formulations of anti-irritability drugs
CA2728213A1 (en) Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
KR20160115995A (ko) 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물
TW202302086A (zh) 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法
JP2021152050A (ja) フマル酸ジメチルを含む医薬ビーズ製剤
US20090311317A1 (en) Modified release tolterodine formulations
CN1161112C (zh) 含氯雷他定和伪麻黄碱的药物胶囊组合物
US20070059368A1 (en) Modified release formulations of anti-irritability drugs
CN115667235A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
AU2008365126A1 (en) Tamsulosin pellets for fixed dose combination
JPWO2021092491A5 (https=)
US20090136550A1 (en) Modified release formulations of diltiazem
US20200315978A1 (en) Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
WO2006130702A2 (en) Modified release formulations of antihypertensive drugs
US20140099378A1 (en) Modified Release Formulations of Anti-Irritability Drugs
WO2026064593A1 (en) Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases
HK40098701A (zh) 森塔纳法啶药物制剂及其制备和使用方法
TW201323014A (zh) 遮味醫藥組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination